Ergomed plc provided preliminary earnings guidance for the full year ended December 31, 2017. For the period, the company's service business saw revenue growth of 35% in 2017 driven by approximately 68% growth in Drug Safety & Medical Information services (DS&MI) which includes PrimeVigilance. The company announced that net service revenues were expected to be approximately £39 million (2016: £29.2 million) and that total revenues were expected to be approximately £47 million, up 21% (2016: £39.2 million). Neither of these expectations has changed. Adjusted EBITDA before R&D for 2017 is expected to be approximately £0.6 million lower than current market consensus of £6.0 million primarily due to foreign exchange losses arising from the translation of foreign currency denominated balance sheet assets and liabilities. In addition, R&D expense is expected to be £0.3 million higher than current market consensus, primarily due to faster than anticipated completion of the PeproStat Phase II trial. Combined, these factors result in expected post-R&D adjusted EBITDA of approximately £0.9 million lower than current market consensus. Expectations for 2018 revenue and adjusted EBITDA remain unchanged.